Evidence map›Paper›PMID 30166419›Full record

ArticleCancer research2018

Systematic Analysis of Compounds Specifically Targeting Telomeres and Telomerase for Clinical Implications in Cancer Therapy.

Hee-Sheung Lee, Mar Carmena, Mikhail Liskovykh, Emma Peat, Jung-Hyun Kim, Mitsuo Oshimura, Hiroshi Masumoto, Marie-Paule Teulade-Fichou, Yves Pommier, William C Earnshaw and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Telomerase (Genes · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Synthesis and investigation of quadruplex-DNA-binding, 9-Beilstein journal of organic chemistry · 2020
    Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 5 countries.

Hee-Sheung Lee *Developmental Therapeutics Branch, National Cancer Institute, NIH, Bethesda, MD.
Mar Carmena *Wellcome Trust Centre for Cell Biology, School of Biological Sciences, King's Buildings, University of Edinburgh, Max Born Crescent, Edinburgh, Scotland.ORCID 0000-0002-2352-1066
Mikhail LiskovykhDevelopmental Therapeutics Branch, National Cancer Institute, NIH, Bethesda, MD.
Emma PeatWellcome Trust Centre for Cell Biology, School of Biological Sciences, King's Buildings, University of Edinburgh, Max Born Crescent, Edinburgh, Scotland.ORCID 0000-0001-9975-1012
Jung-Hyun KimDevelopmental Therapeutics Branch, National Cancer Institute, NIH, Bethesda, MD.
Mitsuo OshimuraInstitute of Regenerative Medicine and Biofunction, Tottori University, Tottori, Japan.
Hiroshi MasumotoLaboratory of Cell Engineering, Department of Frontier Research, Kazusa DNA Research Institute, Kisarazu, Chiba, Japan.
Marie-Paule Teulade-FichouChemistry Modelling and Imaging for Biology, CNRS UMR 9187- INSERM U1196 Institute Curie, Research Center, Campus University Paris-Sud, Orsay, France.
Yves PommierDevelopmental Therapeutics Branch, National Cancer Institute, NIH, Bethesda, MD.
William C EarnshawWellcome Trust Centre for Cell Biology, School of Biological Sciences, King's Buildings, University of Edinburgh, Max Born Crescent, Edinburgh, Scotland.ORCID 0000-0002-7191-0621
Vladimir LarionovDevelopmental Therapeutics Branch, National Cancer Institute, NIH, Bethesda, MD. kouprinn@mail.nih.gov larionov@mail.nih.gov.
Natalay KouprinaDevelopmental Therapeutics Branch, National Cancer Institute, NIH, Bethesda, MD. kouprinn@mail.nih.gov larionov@mail.nih.gov.
National Cancer Institute · UAWellcome Centre for Cell Biology · GBKazusa DNA Research Institute · JPTottori University · JPUniversité Paris-Sud · FR

Funding

Study of hereditary prostate cancer and human artificial chromosomesZ01BC010413 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LARIONOV, VLADIMIR · 2000 to 2008
$2.4M
PROTEIN-ASSOCIATED DNA BREAKS AS INDICATOR OF TOPOISOMERASE INHIBITIONZ01BC006150 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI POMMIER, YVES · 1996 to 2008
$1.5M
Biotechnology and Biological Sciences Research Council BB/M018040/1Intramural NIH HHS Z01 BC006150Intramural NIH HHS Z01 BC010413Wellcome Trust 073915
6 · The paper itself

Abstract

The targeting of telomerase and telomere maintenance mechanisms represents a promising therapeutic approach for various types of cancer. In this work, we designed a new protocol to screen for and rank the efficacy of compounds specifically targeting telomeres and telomerase. This approach used two isogenic cell lines containing a circular human artificial chromosome (HAC, lacking telomeres) and a linear HAC (containing telomeres) marked with the

Indexed as

Antineoplastic AgentsCell LineCell Line, TumorCell SurvivalChromatinChromosomesChromosomes, Artificial, HumanDNA DamageDrug DesignHCT116 CellsHumansHydroxamic AcidsMitosisNeoplasmsTelomeraseTelomereAntineoplastic AgentsChromatinHydroxamic AcidsTelomerasetrichostatin A

Identifiers

PMID30166419
PMCPMC6214708
OpenAlexW2888871749

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.